Conditioned Medium From Human Amniotic Mesenchymal Stromal Cells Limits Infarct Size and Enhances Angiogenesis by Danieli, Patrizia et al.
  
 University of Groningen
Conditioned Medium From Human Amniotic Mesenchymal Stromal Cells Limits Infarct Size
and Enhances Angiogenesis
Danieli, Patrizia; Malpasso, Giuseppe; Cluffreda, Maria Chiara; Cervio, Elisabetta; Calvillo,
Laura; Copes, Francesco; Pisano, Federica; Mura, Manuela; Kleijn, Lennaert; de Boer, Rudolf
A.
Published in:
Stem Cells Translational Medicine
DOI:
10.5966/sctm.2014-0253
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2015
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Danieli, P., Malpasso, G., Cluffreda, M. C., Cervio, E., Calvillo, L., Copes, F., ... Gnecchi, M. (2015).
Conditioned Medium From Human Amniotic Mesenchymal Stromal Cells Limits Infarct Size and Enhances
Angiogenesis. Stem Cells Translational Medicine, 4(5), 448-458. https://doi.org/10.5966/sctm.2014-0253
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
Fetal and Neonatal Stem Cells
Conditioned Medium From Human Amniotic
Mesenchymal Stromal Cells Limits Infarct Size and
Enhances Angiogenesis
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ABSTRACT
The paracrine properties of human amniotic membrane-derived mesenchymal stromal cells
(hAMCs) have not been fully elucidated. The goal of the present study was to elucidate whether
hAMCs can exert beneficial paracrine effects on infarcted rat hearts, in particular through cardio-
protection and angiogenesis. Moreover, we aimed to identify the putative active paracrine medi-
ators. hAMCswere isolated, expanded, and characterized. In vitro, conditionedmedium fromhAMC
(hAMC-CM) exhibited cytoprotective and proangiogenic properties. In vivo, injection of hAMC-CM
into infarcted rat hearts limited the infarct size, reduced cardiomyocyte apoptosis and ventricular
remodeling, and strongly promoted capillary formation at the infarct border zone. Gene array anal-
ysis led to the identification of 32 genes encoding for the secreted factors overexpressed by hAMCs.
Among these, midkine and secreted protein acidic and rich in cysteine were also upregulated at the
protein level. Furthermore, high amounts of several proangiogenic factors were detected in hAMC-
CMby cytokine array. Our results strongly support the concept that the administration of hAMC-CM
favors the repair process after acute myocardial infarction. STEMCELLS TRANSLATIONALMEDICINE
2015;4:448–458
SIGNIFICANCE
The demonstration that stem cells repair infarcted hearts mainly through paracrine mechanisms rep-
resents a potential breakthrough. Characterization of therapeutic paracrine mediators could lead to
the possibility of treating acute myocardial infarction (AMI) with a single stem cell-derived molecule
or a mixture. Compared with cell therapy, this approach would be technically easier to translate to
the bedside. An even more straightforward strategy consists of the administration of the entire stem
cell secretome (i.e., conditionedmedium [CM]). Despite these potential advantages, this approach has
not been thoroughly investigated using human cells. This study shows that CM of fetal stromal cells
(humanamnioticmembrane-derivedmesenchymal stromal cell [hAMC]-CM), derived fromanethically
acceptable source such as the placenta, can repair infarcted hearts without the need for any manipu-
lation. The use of hAMC-CMmight be readily translated to the clinical arena in the setting of AMI upon
demonstration of its effectiveness in a large animal model.
INTRODUCTION
Adult stemcell therapy is a promising approach to
repair postischemicmyocardial damage [1]. In par-
ticular, transplantation of adult bone marrow-
derived mesenchymal stromal cells (BM-MSCs)
has provided encouraging results in animal models
of myocardial infarction, in terms of both pre-
vention of left ventricular (LV) remodeling and
recovery of cardiac function; however, the mech-
anisms of action are still unclear [2]. Differenti-
ation of BM-MSCs into cardiomyocytes (CMCs)
occurs at a very low frequency [3], and it has been
convincingly proved thatMSCs, through the secre-
tion of soluble paracrine factors [4], protect the
heart [5, 6], promote neovascularization [7], pre-
serve cardiacmetabolism [8], andmediate endoge-
nous regeneration via activation of resident cardiac
progenitor cells [9].
The demonstration of stem cell paracrine
mechanisms inmyocardial repair represents a step
forward inthetranslationofcell-basedtherapies to
the clinical arena, because it might be possible to
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FETAL AND NEONATAL STEM CELLS
use soluble factors rather than MSCs to treat ischemic damage.
This is particularly true in the acute setting, in which cardiac
protection, rather than tissue regeneration, could be consid-
ered a reasonable therapeutic goal.
Recently, it has been reported that multipotentMSCs of fetal
origin can be isolated from the amnioticmembrane of humanpla-
centa (hAMCs) [10]. These cells display awidephenotypic and cel-
lular plasticity [11, 12], are immunologically tolerated [13], and
are apparently able to differentiate into mature and competent
CMCs in vitro and regenerate cardiac tissue in vivo. However,
the paracrine properties of hAMCs have never been investigated
in depth. Therefore, we aimed to verify whether hAMCs can exert
beneficial paracrine effects. In particular, we tested the effects of
conditioned medium (CM) obtained from hAMCs (hAMC-CM) on
cardiac protection and neovascularization both in vitro and in
vivo. Moreover, we searched for putative active soluble factors
mediating the paracrine effects exerted by the hAMCs.
MATERIALS AND METHODS
Isolation and Culture of hAMCs
Human term placentas were donated by healthy mothers under-
going cesarean section. The Ethical Committee of the Fondazione
IRCCS Policlinico SanMatteo approved the study, which was per-
formed inaccordancewith theDeclarationofHelsinki. All samples
were collected after obtaining informed consent from the
donors. Fragments of the amniotic membrane were digested in
0.25% trypsin-EDTA for 2 hours and subsequently in 50 U/ml col-
lagenase for 2 hours (Sigma-Aldrich, St. Louis, MO, http://www.
sigmaaldrich.com) in Hanks’ balanced salt solution (Celbio,
EuroClone Group, Milan, Italy, http://www.euroclone.it). The su-
pernatant was collected and centrifuged at 200g for 10 minutes.
Harvested cellswere cultured inpolystyrene culture dishes (Corn-
ing Inc., Corning, NY, http://www.corning.com) at 37°C with an
atmosphere of 5% CO2 and 95% N2 and in a-minimum essential
medium (Celbio EuroClone Group) supplemented with 10% fetal
bovine serum, 2mmol/l L-glutamine, 100U/ml penicillin, and 100
mg/ml streptomycin (all from Gibco, Life Technologies, Carlsbad,
CA, http://www.lifetechnologies.com). hAMCs were selected by
plastic adherence and propagated in culture.
Generation of Conditioned Medium
hAMC-CM and human dermal fibroblast CM (fib-CM) were gen-
erated as follows: 90% confluent cells were fed with serum-
free Dulbecco’s modified Eagle medium (DMEM) high glucose
and incubated for 36 hours at 37°C. Control medium (CTRL-M)
was obtained under the same conditions in the absence of cells.
Cell debris was precipitated by centrifugation at 4°C at 4,000g,
and CM was transferred to a new tube stored at 280°C until
needed. For the in vitro experiments, we used a 1:1 ratio of target
cells/hAMCs or fibroblasts. For example, for 1,000 target cells, we
used CM produced by 1,000 cells (hAMCs or fibroblasts).
Concentrated CM for animal experiments was generated as
follows: hAMC or fibroblasts were fed with serum-free DMEM
high glucose and cultured for 36 hours. Themediumwas then col-
lected, and the cells were counted for normalization purposes.
For each animal, we usedmedium generated by 23 106 cells. Af-
ter removing cell debris as described, the supernatant was trans-
ferred to dedicated ultrafiltration tubes with 3,000 nominal
molecular weight limit (Amicon Ultra-3K device; EMD Millipore,
Bedford, MA, http://www.emdmillipore.com), concentrated by
centrifugation at 4,000g for 1 hour at 4°C and desalted according
to the manufacturer’s protocol. The final volume was 150 ml per
single dose. CM was frozen at 280°C and used in subsequent
experiments.
H9c2 Cell Culture and Hypoxia/Reoxygenation Protocol
TheH9c2 embryonic rat heart-derived cell linewas obtained from
the American Type Culture Collection (CRL-1446) and cultured
according to the manufacturer’s protocol. Before each experi-
ment, H9c2 cells were serum starved for 24 hours to stop cell pro-
liferation. To induce hypoxia/reoxygenation (H/R) injury, H9c2
cells were incubated under hypoxic conditions for 6 hours inside
an airtight Plexiglas chamber with an atmosphere of 5% CO2 and
95% N2 at 37°C. The oxygen level in the chamber was,0.5% (ox-
ygen analyzer MAXO2; Maxtec, Salt Lake City, UT, http://www.
maxtec.com). H9c2 cells were then reoxygenated in a normoxic
environment at 37°C for 18 hours in the presence of CTRL-M,
hAMC-CM, or fib-CM.
Viability and Apoptosis Assays
CellTiter96 Aqueous One Solution Cell viability assay (MTS)
(Promega, Madison, WI, http://www.promega.com) was used
according to the manufacturer’s instructions. terminal deoxynu-
cleotidyl transferasedUTPnick-end labeling (TUNEL)wasperformed
using DeadEnd Fluorometric TUNEL System Assays (Promega)
according to a standard protocol. Nuclei were stained with Hoechst
33258 (Sigma-Aldrich). The samplesweremountedwithVectashield
mountingmedium (Vector Laboratories Inc., Burlingame,CA,http://
www.vectorlabs.com) and examined using a Zeiss Axio Observer Z1
Apotome microscope (Carl Zeiss, Milan, Italy, http://www.zeiss.
com). Caspase-3 activation was measured by Western blot and
the colorimetric activity assay kit (Sigma-Aldrich), according to the
manufacturer’s instructions.
Endothelial Progenitor Cell Migration and
Matrigel Assay
The migration assay was performed using a modified Boyden
chamber (Transwell; Corning Inc.) assay. In brief, endothelial pro-
genitor cells (EPCs) were seeded on a polycarbonate membrane
(8-mmpores) in 24-well Transwell plates in the presence of endo-
thelial growth medium 2 (EGM2) alone or supplemented with 10
ng/ml stromal cell derived factor-1a (SDF-1a; positive control),
CTRL-M (negative control), or hAMC-CM or fib-CM at different
concentrations (13, 103, and 503). After 10 hours, EPCs that
had migrated to the lower side of the membrane were counted
in 5 random microscopic fields. For the angiogenesis assay, EPCs
were seeded in 15 mg/ml Matrigel (Cultrex BME; Trevigen, Gai-
thersburg, MD, http://www.trevigen.com) in the presence of
hAMC-CM or fib-CM at different concentrations (13, 103,
203). CTRL-M and EGM2were used as negative and positive con-
trols, respectively. Tube formation was assessed after 5, 24, 48,
and 72 hours. The images were captured with a camera con-
nected to a phase-contrast microscope. We performed three in-
dependent experiments, and the number of branch points was
manually counted.
Surgical Procedures and Animal Study Design
Before surgery, the rats were randomized to 3 groups. The con-
trol rats received a saline injection, and the CM-treated rats
Danieli, Malpasso, Ciuffreda et al. 449
www.StemCellsTM.com ©AlphaMed Press 2015
received either hAMC-CM or fib-CM. We used male Sprague-
Dawley rats, weighing 175–200 g (Charles River Research Mod-
els and Services, Calco, Italy, http://www.criver.com). The rats
were anesthetized by administering 5% isoflurane during oxy-
gen delivery inside an induction chamber and pretreated with
ampicillin (100 mg/kg) and carprofen (5 mg/kg). The rats were
intubated endotracheally, artificially ventilated with a rodent
ventilator, and electrocardiographically monitored throughout
the surgical procedures. The chest was opened, and the heart
was exteriorized through the intercostal space. To induce ische-
mic injury, the left anterior descending coronary artery (LAD)
was ligated for 30 minutes. Ischemia was confirmed by bleach-
ing of the anterior wall of the left ventricle (LV) and ST elevation
on the electrocardiogram (ECG). After occlusion, the LAD liga-
ture was released, and reperfusion was confirmed by the re-
storation of a bright red tissue color and the presence of
arrhythmias monitored by the ECG trace. After 10minutes, a to-
tal of 150 ml of saline, hAMC-CM, or fib-CM was injected into 5
different sites of the infarct border zone. After 48 hours, 10 rats
per group were sacrificed for quantification of the infarct size
and apoptotic index. The remaining rats (n = 10 per each group)
were sacrificed after 30 days for capillary density quantification
and morphometric analysis. The investigators responsible for
surgery and injections were unaware of the treatment groups.
All procedures for the care and treatment of the rats were per-
formed according to the approved protocols and animal welfare
regulations of the University of Pavia Ethical Committee and the
Animal Care Committee of the Italian Ministry of Health (in ac-
cordance with Italian DL-116/92 and the Directive 2010/63/EU
of the European Parliament and the Council).
Infarct Size Quantification
After 48 hours, the rats were sacrificed to determine the infarct
size. The rats were anesthetized and ventilated, and the thorax
was surgically opened.We performed a small excision at the level
of the right atrium and then started heart perfusion with
phosphate-buffered saline containing heparin. When the heart
was bleached, the LAD was reoccluded using the silk suture left
in place after the first surgery, the pulmonary artery and aorta
were clamped, and 2 3 106 fluorescent microspheres, 10 mm
in diameter (540/560 nm; Molecular Probes; Life Technologies)
were injected into the LV cavity. After 15 seconds, the clamps
were removed, and the heartwas immediately arrested by inject-
ing 0.2 N KCl, removed from the chest, and manually sectioned
transversally from the apex to the base into five 2-mm-thick
biventricular sections.
To quantify the area at risk (AAR) and the infarct size (IS), the
heart sections were incubated in a 1% 2,3,5-triphenyltetrazolium
chloride solution (Sigma-Aldrich) at 37°C for 5 minutes and fixed
in 10% phosphate-buffered formalin. Both sides of each section
were photographed under fluorescent andwhite light using a dig-
ital camera connected to a fluorescent stereomicroscope (Axio
Zoom V16; Carl Zeiss). The total LV area, the infarct scar area,
and the perfused zonewere tracedmanually andmeasured using
the software ImageJ (NIH, Bethesda, MD, USA, http://www.
imagej.nih.gov/ij/, 1997–2012). The AAR, identified as the zone
not reached by the fluorescent microspheres, was obtained by
subtracting the perfused area from the total LV area. The IS,
expressed as a percentage, was calculated by dividing the infarct
area of each section by the corresponding AAR andmultiplying by
100. For each heart, the mean of the IS/AAR was calculated. The
investigators conducting the experimentwere unaware of the ex-
perimental groups.
Detailed methods describing the TUNEL and immunohisto-
chemical analyses are reported in the supplemental online data.
Gene Array
Total RNA was isolated from cultured hAMCs (n = 8), and fibro-
blasts (n = 6) after 48 hours of serum starvation. RNA was
extracted with the Trizol reagent (Life Technologies) following
the manufacturer’s instructions. RNA amplification and labeling
was performed with the Illumina TotalPrep 96 RNA Amplification
Kit (Applied Biosystems, http://www.appliedbiosystems.com).
Human HT-12 V3 Expression Bead Chip arrays (Illumina, San
Diego, CA, http://www.illumina.com), targeting 37,812 anno-
tated genes with 48,813 different probes designed using the
RefSeq (Build 36.2, Release 22) and the UniGene (Build 199) data-
bases (National Center for Biotechnology Information, Bethesda,
MD, http://www.ncbi.nlm.nih.gov) were processed according to
the manufacturer’s protocol. The slides were scanned using an
IlluminaBeadArray Reader, anddatawere analyzedwithGenome
Studio and Genespring GX software (Agilent Technologies Santa
Clara, CA, http://www.agilent.com).
The data discussed in the present report have been deposited
inNCBI’s Gene ExpressionOmnibus [14] and are accessible through
GEO Series accession number GSE61153 (available at http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE61153).
Gene array data were validated by quantitative reverse tran-
scription polymerase chain reaction (PCR) using SYBR green
(Applied Biosystems) on a 7900HT Fast Real-Time PCR System
(Applied Biosystems) according to standard procedures.
Statistical Analysis
All results arepresentedas themean6SD. Statistical analysiswas
performedwith the standard parametric test one-way analysis of
variance (ANOVA) using the Bonferroni method. The nonpara-
metric ANOVA Kruskal-Wallis test was used in the case of nonho-
mogeneous variances. For cytokine array analysis, statistical
significance was determined using the unpaired t test. The
Mann-Whitney U test was applied after evaluation of nonhomo-
geneous variances. All statistical calculations were made using
InStat software (GraphPad Software, Inc., San Diego, CA,
http://www.graphpad.com).
Gene array data were analyzed using the Genome Studio and
Genespring GX software (Agilent Technologies). The genes with
significantly different levels of expression were chosen based
on a log-twofold change .2 in gene expression, t test p , .05,
and corrected for multiple testing using the Benjamini-
Hochberg method.
All other methods are described in the supplemental online
data.
RESULTS
The hAMCs isolated in our laboratory displayed the phenotype
typical of MSC. They stained positive for CD90, CD105, CD73,
human leukocyte antigen (HLA)-ABC and negative for CD45,
CD34, CD14, CD31, CD133, HLA-DR, and CD80. They also effi-
ciently differentiated into both osteocytes and adipocytes in
vitro (Fig. 1).
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The results of several in vitro assays demonstrated that the
factors secreted by hAMCs are cytoprotective and proangio-
genic. First we showed that hAMC-CM prevents cell death.
When rat H9c2 cardiomyoblasts were exposed to H/R in the
presence of hAMC-CM, a significant increase in cell viability
was observed compared with those in CTRL-M (+2.6-fold; p ,
.001) or fib-CM (+1.7-fold; p , .001) (Fig. 2A). In particular,
hAMC-CM reduced H9c2 apoptotic nuclear fragmentation com-
pared with both CTRL-M (256% p , .001) and fib-CM (249%;
p , .001) and prevented caspase-3 cleavage (Fig. 2B2D). The
cytoprotective effects paralleled the concomitant inhibition
of both the stress-activated protein kinase/Jun amino-
terminal kinase (SAPK/JNK) and p38 mitogen-activated protein
kinase (p38 MAPK) proapoptotic pathways and the activation
of the extracellular signal-regulated kinase 1/2 mitogen-
activated protein kinase (ERK1/2 MAPK); the Akt pathway
was not involved (Fig. 2E). Moreover, hAMC-CM led to the
concomitant upregulation of the anti-apoptotic genes B-cell
lymphoma2 and signal transducer and activator of transcription
3 and the downregulation of proapoptotic factors Bcl-2
antagonist/killer 1, tumor necrosis factor-a, and Fas ligand
(FasL) (Fig. 2E).
We then collected data strongly suggesting that hAMCs pos-
itively affect angiogenesis. hAMC-CM remarkably promoted EPC
migration in a dose-dependentmanner. The number ofmigrating
EPCs fedwith hAMC-CMat 13 concentrationwas significantly in-
creased compared with both CTRL-M (+2.6-fold; p, .01) and fib-
CM even when concentrated 503 (+50%; p , .01) (Fig. 3A).
Figure1. Characterizationofhumanamnioticmembrane-derivedmesenchymal stromal cells (hAMCs). (A): Fluorescence-activated cell sorting
analysis of hAMCs at passage 3. (B): Reverse transcription-polymerase chain reaction analysis for osteocyte markers osteopontin (band 1), ca-
thepsin K (band 2), and bone sialoprotein (band 3) or adipocyte markers peroxisome proliferation-activated receptor g (band 5) and adipose
differentiation-related protein (band 6), after an osteogenic or adipogenic differentiation assay. Glyceraldehyde 6-phosphate dehydrogenase
(bands 4 and 7) was used as an endogenous control. (C): Cytochemical analysis: alkaline phosphatase activity assay (bright field, scale bar = 100
mm) andVonKossa staining (bright field, scale bar = 100mm)of hAMCs after osteogenic induction andOil RedO staining (bright field, scale bar =
50mm) of hAMCs at the end of the adipogenic differentiation assay. Data are representative of three independent experiments. Abbreviation:
HLA, human leukocyte antigen.
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The chemoattractive effect of hAMC-CMat 13was comparable to
that exerted by the potent chemoattractant SDF-1a, and, at the
503 concentration, themigration response tohAMC-CMwaseven
higher than in the presence of SDF-1a (+58%; p , .01) (Fig. 3A).
In addition, the Matrigel assay showed a marked increase in capil-
lary density when EPCs were fed with hAMC-CM compared with
CTRL-M (+3.18-fold; p , .001) or fib-CM (+16-fold; p , .001)
(Fig. 3B). Dose-response experiments demonstrated that EPC tube
formation was enhanced in the presence of hAMC-CM 203
compared with the lower concentrations, 13 (+32%; p , .001)
and 103 (+21%; p, .001) (Fig. 3C).With fib-CM,we also observed
a dose-dependent effect, but the number of branches per fieldwas
significantly lowercomparedwithhAMC-CMateachconcentration
tested (Fig. 3C). Time-courseexperiments showed that, in thepres-
enceofhAMC-CM,capillary-like structureswerevisibleasearlyas5
hoursandwerestill presentat24,48,and72hours. In contrast, very
few capillaries were observed at the same time points when EPCs
were grown in fib-CM (Fig. 3D).
To examine the in vivo relevance of our in vitro findings, we
studied the effects of intramyocardial injection of concentrated
Figure2. Cytoprotective effect of hAMC-CM in vitro. (A):MTSviability assay. (B):Quantitative analysis and representative imagesof the TUNEL
assay. Nuclei are shown in blue, andTUNEL+ in green. (C):Colorimetric assay of caspase-3 activity. (D): Immunoblotting for cleaved caspase-3 (17
kDa). (E): Representative images of Western blot (left) and reverse transcription-polymerase chain reaction (right) analysis. p, p, .001 versus
basal normoxia;†,p, .001 versus CTRL-Mand fib-CM; ‡,p, .001 versus CTRL-M; x,p, .01 versus fib-CM.All data expressed as themean6 SD.
Data are representative of three independent experiments. Abbreviations: Bak1, Bcl-2 antagonist/killer 1; Bcl-2, B-cell lymphoma 2; CTRL-M,
control medium; ERK1/2 MAPK, extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase; FasL, Fas ligand; fib-CM, human
dermal fibroblast conditioned medium; GAPDH, glyceraldehyde 6-phosphate dehydrogenase; hAMC-CM, conditioned medium obtained from
human amniotic membrane-derived mesenchymal stromal cells; p, phosphorylated; p38MAPK = p38mitogen-activated protein kinase; SAPK/
JNK, stress-activated protein kinase/Jun amino-terminal kinase; Stat3, signal transducer and activator of transcription 3; TNF-a, tumor necrosis
factor-a; TUNEL, terminal deoxynucleotidyl transferase dUTP nick-end labeling.
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CM using a well-established model of ischemia/reperfusion (I/R)
injury in rats. The data on IS support our in vitro cytoprotective
results. The infarct zone in the saline-treated group was 46% 6
7% of the AAR. Intramyocardial injection of concentrated
hAMC-CM limited IS by 28.5% (p, .01) and 28.3% (p, .01) com-
pared with saline and fib-CM, respectively (Fig. 4A). In the hearts
treated with hAMC-CM, the number of TUNEL+ CMC nuclei at the
infarct border zone was reduced compared with both saline
(243.4%; p, .001) and fib-CM (239.4%; p, .001) (Fig. 4B), in-
dicating a remarkable anti-apoptotic effect.
The limitation in IS obtained with hAMC-CM resulted in better
ventricular remodeling, as documented by morphometric analysis
performedat1month.Measurementsof theLVwall thicknessdem-
onstrated that administration of hAMC-CM prevented the thinning
of the anterior wall compared with both saline (+27%; p, .01) and
fib-CM (+30%; p, .01). Moreover, the scar area in the hAMC-CM-
treated hearts was 42.9% (p, .01) and 52.2% (p, .001) smaller
than those treated saline and fib-CM, respectively (Fig. 4C).
We then quantified the capillary density to examine the pos-
sible contribution of neoangiogenesis in the myocardial repair
process. Isolectin immunostaining showed that 30 days after
hAMC-CM injection, the number of capillaries at the infarct bor-
der zonewas100% (p, .001) and36% (p, .05) higher compared
with saline and fib-CM, respectively (Fig. 5). These data parallel
our in vitro results and confirm that hAMC-CM is proangiogenic.
Next, we searched for putative activemediators of cardiopro-
tection and angiogenesis using a combined genome-wide and
cytokine array approach. A comparison of the gene expression
profiles (Fig. 6A) revealed that 1,682 genes were expressed at
significantlydifferent levelsbyhAMCandfibroblasts.Of thosegenes,
647 were significantly upregulated in hAMC (supplemental online
Table 2) and 131 of these by more than twofold (supplemental
online Table 3). Gene Ontology (GO) functional annotation anal-
ysis was performed on this latter group of 131 genes. Bar graphs
reporting the percentage of annotated genes in each group
are illustrated in supplemental online Figures 1 and 2 (GO
Figure 3. hAMC-CMpromotes angiogenesis in vitro. (A):Boyden chambermigration assay. p, p, .01 versus CTRL-M and fib-CM13, 103, and
503; †, p, .001 versus CTRL-M; x,p, .01 versus SDF-1a; ‡, p, .01 versus hAMC-CM13 and 103. (B):Representative images of EPCs cultured
inMatrigel for 5 hours in the presence of CTRL-M, EGM2 (growthmedium), hAMC-CM, or fib-CM and quantification of the number of branches
per field. Scale bar = 200mm. p, p, .001 versus CTRL-M and fib-CM. (C): Representative images of EPCs cultured inMatrigel for 24 hours in the
presence of hAMC-CM or fib-CM at 13, 103, or 203. Bars summarize the quantitative analysis. Scale bar = 200mm. p, p, .001 versus fib-CM
13, 103, and 203; x, p, .001 versus hAMC-CM 13 and 103; †, p, .05 versus fib-CM 13; ‡, p, .05 versus fib-CM 103. (D): Representative
images of EPCs cultured inMatrigel in the presence of hAMC-CM203 or fib-CM203 for 5, 24, 48, and 72 hours; bars represent the quantitative
analysis. Scale bar = 200mm. p, p, .001 versus fib-CM. All data are expressed as themean6 SD. Data are representative of three independent
experiments. Abbreviations: CTRL-M, controlmedium; EGM2, endothelial growthmedium2; EPCs, endothelial progenitor cells; fib-CM, human
dermal fibroblast conditioned medium; hAMC-CM, conditioned medium obtained from human amniotic membrane-derived mesenchymal
stromal cells; SDF-1a, stromal cell derived factor-1a.
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for cellular component and GO for biological process, respec-
tively). The lists of genes belonging to each enriched group are
listed in supplemental online Tables 4 and 5. Significant GO terms
identified by cellular component analysis were mostly related
to the extracellular region (GO:0005576), extracellular matrix
(GO:0031012), and collagen (GO:0005581), suggesting that the
expression of these secreted factors is highly enriched in hAMCs.
Furthermore, when a search for a correlation with the biological
function of the upregulated genes was performed, GO terms
involving cell adhesion (GO:0007155), biological adhesion
(GO:0022610), response to wounding (GO:0009611), extracellu-
lar matrix organization (GO:0030198), blood vessel development
(GO:0001568), vasculature development (GO:0001944), collagen
fibril organization (GO:0030199), regulation of cell adhesion
(GO:0030155), response to oxidative stress (GO:0006979), and
response to reactive oxygen species (GO:0000302)were themost
significantly enriched terms.
A thorough individual study of the 32 genes annotated with
the GO term extracellular region (GO:0005576), listed in
supplemental online Table 1, led to the identification of midkine
(MDK; +2.6-fold vs. fibroblasts) and secreted protein, acidic,
cysteine-rich (SPARC; +2.4-fold vs. fibroblasts), as interesting pu-
tativeparacrine cardioprotectivemediators [15, 16].Quantitative
polymerase chain reaction confirmed the data obtained with the
array, documenting that, compared with fibroblasts, both MDK
(+8-fold; p , .001) and SPARC (+5.8-fold; p , .001) were in-
creased in hAMCs (Fig. 6B). Western blot analysis of these pro-
teins in CM samples confirmed that both MDK and SPARC were
highly secreted in hAMC-CM compared with fib-CM (Fig. 6C).
We also identified several genes encoding for putative secreted
proteins with unknown functions that might potentially exert
beneficial effects on the ischemic myocardium (data not shown).
Finally, through cytokine antibody array, we demonstrated
that hAMCs produce high amounts of several proangiogenic fac-
tors that likelymediate the effects observed on EPCs and capillary
formation (Fig. 7). hAMCs secreted all 20 cytokines assayed.
Among these, angiogenin, platelet-derived growth factor-BB
(PDGF-BB), basic fibroblast growth factor (bFGF), insulin-like
growth factor 1 (IGF-1), thrombopoietin, vascular endothelial
growth factor (VEGF), and VEGF-D were highly enriched in
hAMC-CM compared with fib-CM (p, .05).
DISCUSSION
Acute myocardial infarction (AMI) remains the leading cause of
mortality and morbidity worldwide [17]. Timely pharmacological
Figure 4. Effects of hAMC-CMon cardioprotection and ventricular remodeling in vivo. (A): Infarct size assessment (n=10 animals per group). p,
p, .01 versus saline and fib-CM. (B): TUNEL assay: a-sarcomeric actin in red, nuclei in blue, and TUNEL+ in green (white arrows). Scale bar = 50
mm. p, p, .001 versus saline and fib-CM. Apoptotic index was quantified with 10,000 cardiomyocytes. (C): Quantitative analysis of LV mor-
phometric parameters (n=8animals per group)were calculated as described in the supplemental onlinedata.p,p, .01 versus saline and versus
fib-CM; †, p , .001 versus fib-CM; x, p , .01 versus saline. Abbreviations: AAR, area at risk; CMCs, cardiomyocytes; fib-CM, human dermal
fibroblast conditioned medium; hAMC-CM, conditioned medium obtained from human amniotic membrane-derived mesenchymal stromal
cells; LV, left ventricular; TUNEL, terminal deoxynucleotidyl transferase dUTP nick-end labeling.
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or mechanical reperfusion of an occluded coronary artery repre-
sents the most effective therapy to spare the cardiac tissue from
ischemic damage [18]. Many adjuvant medications, such as pow-
erful antiplatelet and anticoagulant drugs, have been shown to
further ameliorate the outcome of subjects experiencing AMI.
However, even after the best medical treatment, in many
patients, the IS is still significantly extended, and negative LV
remodeling ensues [17].
With thepresent study,weprovide evidence that hAMCspro-
duce and release factors able to promote cardiac repair. Two
important aspects of stem cell action were studied both in vitro
and in vivo: cardioprotection and neoangiogenesis.
We demonstrated that hAMC-CM strongly protects cardiac-
like cells from H/R injury in vitro. The main mechanism revealed
was inhibitionof cell apoptosis, shownby the reduction innuclear
fragmentation and caspase activation. In the presence of hAMC-
CM, the prosurvival ERK1/2 MAPK pathway is clearly activated
and proapoptotic pathways such as SAPK/JNK and p38 MAPK
are inhibited. Likewise, hAMC-CM activates prosurvival genes
and prevents the activation of proapoptotic genes in cardiac cells.
The cardioprotective effect exerted by hAMC-CMwas alsomean-
ingful in vivo, as verified by the significant limitation in IS and car-
diac apoptosis in rat hearts. The 28.5% limitation in IS observed
after hAMC-CM treatment was comparable to that observed in
infarcted pig hearts treated with ischemic postconditioning,
Figure 5. Proangiogenic effects of hAMC-CM in vivo. Capillary den-
sity was assessed by isolectin B4 immunostaining (green) at both the
border and the remote zone (n = 5 animals per group). Scale bar = 100
mm. p, p, .001 versus saline; †, p, .05 versus fib-CM. All data are
expressed as the mean6 SD. Abbreviations: fib-CM, human dermal
fibroblast conditioned medium; hAMC-CM, conditioned medium
obtained from human amniotic membrane-derived mesenchymal
stromal cells.
Figure 6. Identification of paracrine activemediators. (A): Venn dia-
grams representing the number of detected genes significantly upre-
gulated (left) and upregulated more than twofold (right) in hAMCs
and fibroblasts. (B)qRT-PCR validation analysis ofMDKandSPARCex-
pression in hAMC and fibroblasts. The bar graph represents the fold
increase expression value of hAMC-CM compared with fibroblasts. p,
p, .001. Data are expressed as the mean6 SD. Data are represen-
tative of three independent experiments (two replicates each). (C):
Representative Western blot analysis of MDK (14.6 kDa, left) and
SPARC (35 kDa, right) in hAMC-CM and fib-CM. Data are representa-
tive of three independent experiments. Abbreviations: fib-CM, hu-
man dermal fibroblast conditioned medium; hAMCs, human
amniotic membrane-derived mesenchymal stromal cells; hAMC-
CM, conditioned medium obtained from hAMCs; qRT-PCR, quantita-
tive reverse transcription-polymerase chain reaction; SPARC, se-
creted protein, acidic, cysteine-rich.
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currently considered themost attractive approach to achieve car-
dioprotection [19, 20]. The smaller IS preventedwall thinning and
LV enlargement, as documented by morphometric analysis per-
formed at 1 month.
The effect of hAMC-CM was not limited to cardioprotection.
As demonstrated by in vitro assays and confirmed in vivo, the sol-
uble factors secreted by hAMC strongly promoted neovasculari-
zation. In vitro, the effects triggered by hAMC-CM equaled those
obtained with SDF-1a, and in vivo, hAMC-CM significantly in-
creased the number of capillaries at the infarct border zone
compared with saline. This result is comparable to, if not greater
than, that obtained with other potent proangiogenic therapies,
including injectionof endothelial early outgrowthprogenitor cells
isolated from healthy patients [21], gene therapy with VEGF2
[22], and administration of human recombinant bFGF [23], to
name a few. These results can be partially explained because
several proangiogenic factors are abundantly secreted by hAMCs,
as shown by our cytokine profiling, including VEGF, bFGF, IGF-1,
thrombopoietin, PDGF-BB, angiogenin, and VEGF-D.
Although this was not the main goal of the present study, we
attempted to shed light on the putative soluble mediators of the
observed cardioprotective effects.Weperformedwhole-genome
expressionprofilingonhAMCs,whichcurrently represents amore
comprehensive and technically less demanding method than
Figure 7. Proangiogenic factors present in thehAMC-CM. (A):Representative images of human cytokine antibody arraymembranes (RayBioHuman
AngiogenesisAntibodyarray I,RayBiotech,Norcross,GA,http://www.raybiotech.com)ofCTRL-M,hAMC-CM,andfib-CM. (B):Layoutof themembrane
for the human cytokine antibody array. Positive controls are located in the upper left corner (four spots) and lower right corner (two spots) of each
membrane. (C):Quantitative analysis confirmed that several proangiogenic cytokines are significantlymore abundant in hAMC-CM than in fib-CM. p,
p, .05 versus fib-CM.All data are expressed as themean6 SD. Data are representative of two independent experiments. Abbreviations: bFGF, basic
fibroblast growth factor; CTRL-M, controlmedium; EGF, endothelial growth factor; ENA-78or CXCL5, C-X-Cmotif chemokine 5; fib-CM, humandermal
fibroblast conditioned medium; GRO, growth-regulated oncogene; hAMC-CM, human amniotic membrane-derived mesenchymal stromal cells con-
ditionedmedium; IFN-g, interferon-g; IGF-1, insulin-like growth factor 1; IL, interleukin;MCP-1, monocyte chemoattractant protein-1; Neg, negative;
PIGF, placental growth factor; PDGF, platelet-derived growth factor; Pos, positive; RANTES, regulated on activation, normal T cell expressed and se-
creted; TGF-b1, transforming growth factor-b1; TIMP, tissue inhibitor of metalloproteinase; VEGF, vascular endothelial growth factor.
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proteomics. We identified genes overexpressed in hAMCs com-
pared with fibroblasts. We then focused our genomic analysis
on the genes encoding the secreted proteins, and, by computa-
tional analysis, we identified 32 genes encoding known secreted
factors. Although this strategy does not provide direct evidence
that these particular factors are responsible for the observed car-
dioprotective effects, it does show that hAMCs overexpress sev-
eral candidate solublemolecules. Furthermore, we evaluated the
function of each individual secreted factor by surveying the pub-
lished data.MDKand SPARC emerged as the twomost interesting
candidates of putative hAMC-secreted proteins exerting prosur-
vival effects on the myocardium. MDK has been shown to reduce
apoptosis via ERK phosphorylation and by Bcl-2 activation inmice
subjected to I/R [24]. In addition, it has been shown that exoge-
nousMDKattenuates LV remodeling and improves long-term sur-
vival after a myocardial infarct by enhancing angiogenesis and
reducing apoptosis via the Akt/PI3-kinase pathway [15, 25, 26].
SPARC exerts a key role in collagen assembly in the extracellular
matrix [16]. The absence of SPARC results in a significant increase
in myocardial rupture and ventricular dysfunction after myocar-
dial infarct [27]. Consistently, overexpression of SPARC by adeno-
viral delivery in wild-type mice 2 days before myocardial
infarction resulted in improved cardiac function and a reduction
in dilation without significant effects on IS [27].
As expected, most of the genes upregulated in the hAMCs
coded either for proteins with unknown function or for secreted
proteins without a previously described cardioprotective func-
tion. Thus, we cannot exclude the fascinating possibility that
among these genes, some might code for powerful novel thera-
peutic molecules that could contribute to the beneficial effects
we have described. The identification of these putative factors
will require many additional studies over the next few years.
For example, the next challenging goal will be to flank the
reported genomic approach with a proteomic and functional ap-
proach aimed at dissecting the complete nature and scope of the
factors involved in the therapeutic effects conferred by the CM
obtained from hAMCs.
It has also been proposed that the beneficial cardioprotective
effects observed after MSC therapy might be mediated by exo-
somes [28]. Exosomes are small vesicles (between 30 and 100
nm in diameter) of endocytotic origin, limited by a lipid bilayer
containing cytosol, and secreted by most cells. In addition to car-
dioprotection, it has been suggested that exosomes can favor an-
giogenesis by modulating the soluble factor production involved
in endothelial and progenitor cell differentiation, proliferation,
migration, and adhesion [29]. The exact mechanism of action
of exosomes is still partially unknown, although it is likely that,
in the end, the real mediators might be the proteins and/or the
microRNA contained inside the exosomes and released by the
microparticles on entry to the target cells [30]. The role of exo-
somes in hAMC paracrine action needs to be elucidated.
CONCLUSION
The demonstration that stem cells secrete therapeutic factors
provides a potential breakthrough. Characterization of those
paracrine mediators could lead to the replacement of stem
cell-based therapy with a soluble factor-based therapy in which
a single or a mixture of molecules would be administered to
patients [31]. A shortcut approach might consist of the adminis-
tration of the entire stem cell secretome (i.e., conditioned me-
dium). This strategy, compared with cell therapy, would be
technically simpler to translate to the bedside.
Despite these potential advantages, this approach has not
been properly investigated using human cells. The only exception
is represented by MSCs derived from embryonic stem cells,
a source that is ethically unacceptable for many patients. Several
strategies have been pursued to modulate and magnify the pro-
duction of paracrine factors [32–34]. However, every additional
manipulation step in the production of a therapeutic cell-derived
product representsahurdle to its clinical translation for both safety
and cost reasons. We have demonstrated that CM of fetal stromal
cells, derived from an ethically acceptable source, such as the pla-
centa, can repair infarcted hearts without the need for any manip-
ulation. Nevertheless, transplantation of stem cells still represents
a reasonable strategy. Our results, contributing to those showing
their direct cardiac regeneration potential and their immunoprivi-
leged phenotype, support the concept that hAMCs are excellent
candidates for cardiac cell therapy.
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